MindWalk (NASDAQ:HYFT) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

MindWalk (NASDAQ:HYFT) released its quarterly earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04), Zacks reports. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%.

MindWalk Price Performance

Shares of MindWalk stock traded up $0.03 during trading hours on Monday, hitting $1.33. The company’s stock had a trading volume of 171,103 shares, compared to its average volume of 358,475. The business has a 50 day moving average price of $1.38 and a two-hundred day moving average price of $1.36. MindWalk has a 12-month low of $0.99 and a 12-month high of $2.99. The company has a market cap of $62.12 million, a PE ratio of -6.05 and a beta of 0.82. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.72 and a current ratio of 2.80.

Analysts Set New Price Targets

Several research firms have recently commented on HYFT. Wall Street Zen raised MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. Zacks Research lowered shares of MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. Finally, HC Wainwright restated a “buy” rating on shares of MindWalk in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.00.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.